FibroGen (FGEN) Cut to “Sell” at ValuEngine

FibroGen (NASDAQ:FGEN) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Several other research firms have also weighed in on FGEN. Mizuho assumed coverage on FibroGen in a report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 target price on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group reiterated a “buy” rating and set a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. William Blair reiterated an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $82.00 target price (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $65.67.

FibroGen (FGEN) traded down $0.35 during mid-day trading on Friday, reaching $47.15. The company’s stock had a trading volume of 481,175 shares, compared to its average volume of 553,823. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. FibroGen has a 52-week low of $19.25 and a 52-week high of $60.15.

In other FibroGen news, insider K Peony Yu sold 2,851 shares of FibroGen stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $51.00, for a total value of $145,401.00. Following the sale, the insider now owns 185,546 shares of the company’s stock, valued at approximately $9,462,846. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas F. Kearns, Jr. sold 18,000 shares of FibroGen stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total value of $813,960.00. Following the completion of the sale, the director now directly owns 156,564 shares in the company, valued at approximately $7,079,824.08. The disclosure for this sale can be found here. Insiders sold a total of 387,982 shares of company stock worth $20,683,362 in the last three months. Company insiders own 13.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new stake in shares of FibroGen in the second quarter valued at about $128,000. Oppenheimer Asset Management Inc. increased its position in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 2,336 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 696 shares during the last quarter. BBR Partners LLC acquired a new stake in shares of FibroGen in the third quarter valued at about $299,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of FibroGen in the third quarter valued at about $299,000. 57.42% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “FibroGen (FGEN) Cut to “Sell” at ValuEngine” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/03/fibrogen-fgen-cut-to-sell-at-valuengine.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply